Investigating the association between environmental contaminants and progression to autoimmune disease
General Audience Summary
The burden of autoimmune diseases is growing worldwide. Type 1 diabetes (T1D), multiple sclerosis (MS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) are autoimmune diseases thought to develop via a complex interplay between inherent genetic risk and environmental exposures that can trigger autoimmunity initially and then lead to clinical disease. Individuals who ultimately develop an autoimmune disease exhibit a period of disease evolution termed ‘preclinical disease’ prior to the onset of clinically apparent disease. These diseases develop on the foundation of genetic risk, which predisposes individuals to developing future disease given certain exposures (both internal and external). The next period is characterized by asymptomatic autoimmunity manifest as the appearance of autoantibodies (in T1D, RA and SLE), which can precede the development of clinical disease by months or years, suggesting that the search for a potential causal exposure should start prior to the appearance of autoantibodies. However, not everyone with autoantibodies progresses to clinical disease, so another time to search for an exposure that may be impacting progression is during the transition from the autoantibody-positive stage to the development of clinical disease. Although there are no known autoantibody biomarkers for the pre-clinical state of MS, increasing evidence suggests there is a prodrome that lasts years prior to the onset of first symptoms and diagnosis of clinical disease. The complete etiologies of these four autoimmune diseases remain largely unknown. Genetic factors are thought to account for about half of the disease risk, suggesting that environmental factors explain the remaining half of the risk. The prevalence of autoimmunity and autoimmune diseases is increasing, which suggests an environmental influence and makes finding the cause of this increase an urgent public health problem. Increasing exposure to a wide range of environmental contaminants and additives may be an explanation for this increase in disease. We are interested in investigating the relationship between exposure to environmental contaminants, such as perand polyfluoroalkyl substance (PFAS), phenols and phthalates and future development of T1D, MS, SLE, and RA in individuals at-risk for these diseases. We will accomplish this by using prospective cohorts of at-risk individuals that are followed for the development of clinical disease. At-risk is defined as having a family history of disease, possessing a genetic risk marker or being autoantibody positive. The overall goal is to identify if environmental contaminants are associated with these autoimmune diseases, and whether there may be a common mechanism behind the effect of environmental contaminants, in order to develop potential environmental interventions that can reduce the risk of autoimmune disease development.
Scientific Abstract
Type 1 diabetes (T1D), multiple sclerosis (MS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) are autoimmune diseases thought to develop via a complex interplay between inherent genetic risk and environmental exposures that can trigger autoimmunity initially and then lead to clinical disease. Individuals who ultimately develop an autoimmune disease exhibit a period of disease evolution termed ‘preclinical disease’ prior to the onset of clinically apparent disease. These diseases develop on the foundation of genetic risk, which predisposes individuals to developing future disease given certain exposures (both internal and external). The next period is characterized by asymptomatic autoimmunity manifest as the appearance of autoantibodies (in T1D, RA and SLE), which can precede the development of clinical disease by months or years, suggesting that the search for a potential causal exposure should start prior to the appearance of autoantibodies. However, not everyone with autoantibodies progresses to clinical disease, so another time to search for an exposure that may be impacting progression is during the transition from the autoantibody-positive stage to the development of clinical disease. Although there are no known autoantibody biomarkers for the pre-clinical state of MS, increasing evidence suggests there is a prodrome that lasts years prior to the onset of first symptoms and diagnosis of clinical disease. Genetic factors are thought to account for about half of the disease risk, suggesting that environmental factors explain the remaining risk. The prevalence of autoimmunity and autoimmune diseases is increasing, which suggests an environmental influence and makes finding the cause of this increase an urgent public health problem. Increasing exposure to a wide range of environmental contaminants and additives may be an explanation for this increase in disease. In this pilot, we will investigate the relationship between exposure to environmental contaminants, such as per- and polyfluoroalkyl substance (PFAS), phenols and phthalates and future development of T1D, MS, SLE, and RA in individuals at-risk for these diseases. We will accomplish this by using four prospective cohorts of at-risk individuals that are followed for the development of clinical disease. At-risk is defined as having a family history of disease, possessing a genetic risk marker or being autoantibody positive. We hypothesize that higher levels (and mixtures) of environmental contaminants are associated with an increased risk of progression to T1D, MS, RA, and SLE. We are well situated to conduct this pilot efficiently as we have access to stored serum samples that were collected prior to the diagnosis/classification of the autoimmune disease. We will measure environmental contaminants using a novel untargeted/targeted hybrid assay for simultaneously quantifying legacy PFAS, mining the untargeted data for novel and emerging PFAS, and untargeted metabolomics profiling of plasticizers and preservatives (phenols and phthalates). We will test the entire set of contaminants by using logistic regression models of individual contaminants, and then for exposures that are significant in individual exposure models, we will use Bayesian kernel machine regression (BKMR) using a probit link to evaluate potential non-linear and interactive associations as well as the effect of the total mixtures. Individuals in these cohorts have been well-described previously and we will have the opportunity to combine the environmental contaminant data with other omics (methylation, genetics), clinical (autoantibodies, inflammation biomarkers) and epidemiological (diet/dietary biomarkers, stress, geocoded environmental exposures) data to conduct an in-depth and comprehensive analysis of how environmental contaminants are affecting the body and disease processes, both within and across disease states. The overall goal is to identify a common mechanism behind the effect of environmental contaminants on these autoimmune diseases, to develop potential environmental interventions that can reduce the risk of autoimmune disease development.